Research
Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's
The Brief
- Mirodenafil (known as AR1001), an oral phosphodiesterase-5 inhibitor, is approved in South Korea to treat erectile dysfunction.
- In the phase III POLARIS-AD trial in people with early Alzheimer's disease, mirodenafil showed mixed results.
- The source text is truncated, so the full trial outcomes are not available here.
Why it matters
It tests whether an existing approved drug could be repurposed for early Alzheimer's disease, but mixed phase III results mean no clear benefit has been established.
Who’s affected
- researchers and clinicians in Alzheimer's disease
- people with early Alzheimer's disease and their families
- #alzheimer's
- #clinical trial
- #drug repurposing
- #phosphodiesterase-5 inhibitor
- #erectile dysfunction
(MedPage Today) -- Mirodenafil (known as AR1001), an oral phosphodiesterase-5 inhibitor approved in South Korea to treat erectile dysfunction, showed mixed results in people with early Alzheimer's disease in the phase III POLARIS-AD trial. The...